Pfizer (PFE) and OPKO Health (OPK) announced that the U.S. FDA has approved NGENLA, a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older who have growth failure due to inadequate secretion of endogenous growth hormone. NGENLA is expected to become available for U.S. prescribing in August 2023.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PFE:
- Opko Health Soars on FDA Approval for Growth Hormone Therapy
- Cantor biotech/biopharma analysts hold analyst/industry conference call
- Cantor Fitzgerald biotech/biopharma to hold analyst/industry conference call
- Cantor Fitzgerald biotech/biopharma to hold a luncheon meeting
- Pfizer and Moderna: The Vaccine Boom is Over, and Shares are Plunging